Skip to main content

Advertisement

SpringerLink
Log in

The utility of tumor marker combination, including serum P53 antibody, in colorectal cancer treatment

  • Original Article
  • Published:
Surgery Today Aims and scope Submit manuscript

Abstract

Purposes

Serum P53 antibody (S-P53Ab) is reportedly an effective screening tool for cancer. The aim of this study is to investigate the clinical significance of tumor markers combination in colorectal cancer (CRC) patients.

Methods

Carcinoembryonic antigen (CEA), carbohydrate 19 - 9 (CA19-9), and S-P53Ab levels were measured before tumor resection. Of the CRC patients with primary tumor resection at Kumamoto University Hospital, a total of 244 with available preoperative data for these three tumor markers were eligible for this study. The associations of the tumor markers with clinicopathological factors and the prognosis were examined using univariate and multivariate analyses.

Results

S-P53Ab positivity was strongly correlated with rectal cancer, depth of tumor invasion, lymph node metastasis, and lymphatic invasion. The ratio of S-P53Ab positivity was higher than that of CEA or CA19-9 in patients with stage 0/I disease. S-P53Ab had no power to predict the prognosis (P = 0.786). The patients with combined CEA and CA19-9 positivity had a significantly poorer overall survival than those with positivity for neither or only one, and combined CEA and CA19-9 positivity was an exclusive independent prognostic factor (P = 0.034).

Conclusions

The clinical significance of S-P53Ab measurement in CRC patients is limited. However, the combination of CEA and CA19-9 levels may be effective for predicting the outcomes of CRC treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Ferrone CR, Finkelstein DM, Thayer SP, Muzikansky A, Fernandez-delCastillo C, Warshaw AL. Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol. 2006;24:2897–902.

    Article  CAS  PubMed  Google Scholar 

  2. Thirunavukarasu P, Sukumar S, Sathaiah M, Mahan M, Pragatheeshwar KD, Pingpank JF, et al. C-stage in colon cancer: implications of carcinoembryonic antigen biomarker in staging, prognosis, and management. J Natl Cancer Inst. 2011;103:689–97.

    Article  PubMed  Google Scholar 

  3. Shimada H, Noie T, Ohashi M, Oba K, Takahashi Y. Clinical significance of serum tumor markers for gastric cancer: a systematic review of literature by the Task Force of the Japanese Gastric Cancer Association. Gastric Cancer. 2014;17:26–33.

    Article  CAS  PubMed  Google Scholar 

  4. Shimada Y, Kido T, Kameyama H, Nakano M, Yagi R, Tajima Y, et al. Clinical significance of perineural invasion diagnosed by immunohistochemistry with anti-S100 antibody in Stage I-III colorectal cancer. Surg Today. 2015;45:1493–500.

    Article  CAS  PubMed  Google Scholar 

  5. Katayama H, Kurokawa Y, Nakamura K, Ito H, Kanemitsu Y, Masuda N, et al. Extended Clavien-Dindo classification of surgical complications: Japan Clinical Oncology Group postoperative complications criteria. Surg Today. 2016;46:668–85.

    Article  PubMed  Google Scholar 

  6. Stiksma J, Grootendorst DC, van der Linden PW. CA 19-9 As a Marker in Addition to CEA to Monitor Colorectal Cancer. Clin Colorectal Cancer. 2014;13:239–44.

    Article  PubMed  Google Scholar 

  7. Duffy MJ, Synnott NC, McGowan PM, Crown J, O’Connor D, Gallagher WM. p53 as a target for the treatment of cancer. Cancer Treat Rev. 2014;40:1153–60.

    Article  CAS  PubMed  Google Scholar 

  8. Suppiah A, Greenman J. Clinical utility of anti-p53 auto-antibody: systematic review and focus on colorectal cancer. World J Gastroenterol. 2013;19:4651–70.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Soussi T. p53 Antibodies in the sera of patients with various types of cancer: a review. Cancer Res. 2000;60:1777–88.

    CAS  PubMed  Google Scholar 

  10. Ochiai H, Ohishi T, Osumi K, Tokuyama J, Urakami H, Seki S, et al. Reevaluation of serum p53 antibody as a tumor marker in colorectal cancer patients. Surg Today. 2012;42:164–8.

    Article  CAS  PubMed  Google Scholar 

  11. Yamaguchi T, Takii Y, Maruyama S. Usefulness of serum p53 antibody measurement in colorectal cancer: an examination of 1384 primary colorectal cancer patients. Surg Today. 2014;44:1529–35.

    Article  CAS  PubMed  Google Scholar 

  12. Sobin LH GM, Wittekind C. TNM classification of malignant tumours. 7th ed. New York: Wiley-Blackwell; 2009.

    Google Scholar 

  13. The Japanese Society for Cancer of the Colon and Rectum. JSCCR guidelines 2005 for the treatment of colorectal cancer. Tokyo: Kanehara & Co, Ltd; 2005.

    Google Scholar 

  14. The Japanese Society for Cancer of the Colon and Rectum. JSCCR guidelines 2010 for the treatment of colorectal cancer. Tokyo: Kanehara & Co, Ltd; 2010.

    Google Scholar 

  15. Watanabe T, Itabashi M, Shimada Y, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer. Int J Clin Oncol 2010. 2012;17(1):21–29.

    Google Scholar 

  16. Chang SC, Lin JK, Lin TC, Liang WY. Genetic alteration of p53, but not overexpression of intratumoral p53 protein, or serum p53 antibody is a prognostic factor in sporadic colorectal adenocarcinoma. Int J Oncol. 2005;26:65–75.

    CAS  PubMed  Google Scholar 

  17. Lechpammer M, Lukac J, Lechpammer S, Kovacevic D, Loda M, Kusic Z. Humoral immune response to p53 correlates with clinical course in colorectal cancer patients during adjuvant chemotherapy. Int J Colorectal Dis. 2004;19:114–120.

    Article  PubMed  Google Scholar 

  18. Shimada H, Ochiai T, Nomura F. Titration of serum p53 antibodies in 1,085 patients with various types of malignant tumors: a multiinstitutional analysis by the Japan p53 Antibody Research Group. Cancer. 2003;97:682–689.

    Article  PubMed  Google Scholar 

  19. Angelopoulou K, Stratis M, Diamandis EP. Humoral immune response against p53 protein in patients with colorectal carcinoma. Int J Cancer. 1997;70:46–51.

    Article  CAS  PubMed  Google Scholar 

  20. Hata K, Yamamoto Y, Kiyomatsu T, Tanaka T, Kazama S, Nozawa H, et al. Hereditary gastrointestinal cancer. Surg Today. 2016;46:1115–1122.

    Article  CAS  PubMed  Google Scholar 

  21. Goel A, Boland CR. Epigenetics of colorectal cancer. Gastroenterology. 2012;143:1442–1460.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Tang R, Ko MC, Wang JY, Changchien CR, Chen HH, Chen JS, et al. Humoral response to p53 in human colorectal tumors: a prospective study of 1209 patients. Int J Cancer. 2001;94:859–863.

    Article  CAS  PubMed  Google Scholar 

  23. Suppiah A, Alabi A, Madden L, Hartley JE, Monson JR, Greenman J. Anti-p53 autoantibody in colorectal cancer: prognostic significance in long-term follow-up. Int J Colorectal Dis. 2008;23:595–600.

    Article  CAS  PubMed  Google Scholar 

  24. Hammel P, Leroy-Viard K, Chaumette MT, Villaudy J, Falzone MC, Rouillard D, et al. Correlations between p53-protein accumulation, serum antibodies and gene mutation in colorectal cancer. Int J Cancer. 1999;81:712–718.

    Article  CAS  PubMed  Google Scholar 

  25. Slattery ML, Curtin K, Wolff RK, Boucher KM, Sweeney C, Edwards S, et al. A comparison of colon and rectal somatic DNA alterations. Dis Colon Rectum. 2009;52:1304–1311.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Lopes A, Bezerra AL, Pinto CA, Serrano SV, de Mell OC, Villa LL. p53 as a new prognostic factor for lymph node metastasis in penile carcinoma: analysis of 82 patients treated with amputation and bilateral lymphadenectomy. J Urol. 2002;168:81–86.

    Article  PubMed  Google Scholar 

  27. Han U, Can OI, Han S, Kayhan B, Onal BU. Expressions of p53, VEGF C, p21: could they be used in preoperative evaluation of lymph node metastasis of esophageal squamous cell carcinoma? Dis Esophagus. 2007;20:379–385.

    Article  CAS  PubMed  Google Scholar 

  28. Otto N, Schulz P, Scholz A, Hauff P, Schlegelberger B, Detjen KM, et al. The proline TP53 variant stimulates likely lymphangiogenesis in an orthotopic mouse model of pancreatic cancer. Br J Cancer. 2012;106:348–357.

    Article  CAS  PubMed  Google Scholar 

  29. Duffy MJ, van Dalen A, Haglund C, Hansson L, Klapdor R, Lamerz R, et al. Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines. Eur J Cancer. 2003;39:718–727.

    Article  CAS  PubMed  Google Scholar 

  30. Hanke B, Riedel C, Lampert S, Happich K, Martus P, Parsch H, et al. CEA and CA 19-9 measurement as a monitoring parameter in metastatic colorectal cancer (CRC) under palliative first-line chemotherapy with weekly 24-hour infusion of high-dose 5-fluorouracil (5-FU) and folinic acid (FA). Ann Oncol. 2001;12:221–226.

    Article  CAS  PubMed  Google Scholar 

  31. Narimatsu H, Iwasaki H, Nakayama F, Ikehara Y, Kudo T, Nishihara S, et al. Lewis and secretor gene dosages affect CA19-9 and DU-PAN-2 serum levels in normal individuals and colorectal cancer patients. Cancer Res. 1998;58:512–518.

    CAS  PubMed  Google Scholar 

  32. La Greca G, Sofia M, Lombardo R, Latteri S, Ricotta A, Puleo S, et al. Adjusting CA19-9 values to predict malignancy in obstructive jaundice: influence of bilirubin and C-reactive protein. World J Gastroenterol. 2012;18:4150–4155.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med. 1993;328:1365–1371.

    Article  CAS  PubMed  Google Scholar 

  34. Lieberman DA, Weiss DG. One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon. N Engl J Med. 2001;345:555–560.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto, 860-8556, Japan

    Ryuma Tokunaga, Yasuo Sakamoto, Shigeki Nakagawa, Naoya Yoshida & Hideo Baba

Authors
  1. Ryuma Tokunaga
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yasuo Sakamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shigeki Nakagawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Naoya Yoshida
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hideo Baba
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hideo Baba.

Ethics declarations

Conflict of interest

Ryuma Tokunaga and other co-authors have no conflicts of interest.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 62 KB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tokunaga, R., Sakamoto, Y., Nakagawa, S. et al. The utility of tumor marker combination, including serum P53 antibody, in colorectal cancer treatment. Surg Today 47, 636–642 (2017). https://doi.org/10.1007/s00595-016-1464-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00595-016-1464-8

Keywords

Search

Navigation